Valuing the economic benefits of complex interventions: When maximising health is not sufficient

Health Economics (United Kingdom)

Volumn 22, Issue 3, 2013, Pages 258-271

  Payne, Katherine ^a   McAllister, Marion ^a,b   Davies, Linda M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Nowgen A Centre for Genetics in Healthcare   (United Kingdom)

Author keywords

benefits; complex interventions; economic evaluation; genetics; QALYs

Indexed keywords

ARTICLE; COMPLEX INTERVENTION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; EMPOWERMENT; GENETIC COUNSELING; GENETIC SCREENING; GENETIC SERVICE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROMOTION; HEALTH SERVICE; HEALTH STATUS; HIGH THROUGHPUT SEQUENCING; HUMAN; INTEGRATED HEALTH CARE SYSTEM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR;

COST-BENEFIT ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GREAT BRITAIN; HEALTH POLICY; HUMANS; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE;

EID: 84873412581     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.2795     Document Type: Article

References (89)

1. Anderson RM, Funnell MM, Fitzgerald JT, et al,. 2000. The Diabetes Empowerment Scale: A measure of psychosocial self-efficacy. Diabetes Care 23: 739-743.
2. Beck AT, Steer RA, Garbin MG,. 1988. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clinical Psychology Review 8: 77-100.
3. Berkenstadt M, Shiloh S, Barkai G, Katznelson MbM, Goldman B,. 1999. Perceived personal control (PPC): a new concept in measuring outcome of genetic counselling. American Journal of Medical Genetics 82: 53-59.
4. Birch S, Melnikow J, Kuppermann M,. 2003. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Economics 12: 879-884.
5. Brain K, Gray J, Norman P, et al,. 2000. Randomized Trial of a Specialist Genetic Assessment Service for Familial Breast Cancer. Journal of the National Cancer Institute 92 (16): 1345-1351.
6. Bulsara C, Styles I, Ward AM, et al,. 2006. The Psychometrics of the Patient Empowerment Scale. Journal of Psychosocial Oncology 24: 1-16.
7. Byrne R, Davies L, Morrison AP,. 2010. Priorities and preferences for the outcomes of treatment of psychosis: A service user perspective. Psychosis DOI: 10.1080/17522430903456913.
8. Carlson JJ, Henriskon NB, Veenstra DL, et al,. 2005. Economic analysis of human genetics services: a systematic review. Genetics in Medicine 7 (8): 519-523.
9. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al,. 1993. The functional assessment of cancer therapy scale: development and validation of the general measure. Journal of Clinical Oncology 11: 570-579.
10. Cella D, Hughes C, Peterman A, Chang C, Peshkin BN, Schwartz MD, et al,. 2002. Brief assessment of concerns with genetic testing for cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) Questionnaire. Health Psychology 21 (6): 564-572.
11. Chalkidou K, Culyer A, Naidoo B, Littlejohns P,. 2008. Cost-effectiveness public health guidance: asking questions from the decision-maker's viewpoint. Health Economics 17: 441-448.
12. Chamberlain J,. 1978. Human benefits and costs of a national screening programme for neural-tube defects. Lancet 2 (1803): 1293-1296.
13. Claxton KP,. 2007. OFT, VBP: QED? Health Economics 16: 545-558.
14. Claxton KP, Sculpher MJ, Culyer AJ,. 2007. Mark versus Luke? Appropriate methods for the evaluation of public health interventions. CHE Research Paper 31, The University of York: York.
15. Coast J, Flynn TN, Natarajan L, Sproston K, Lewis J, Louviere JJ, Peters TJ,. 2008c. Valuing the ICECAP capability index for older people. Social Science & Medicine 67: 874-882.
16. Coast J, Smith R, Lorgelly P,. 2008a. Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Social Science & Medicine 67: 1190-1198.
17. Coast J, Smith R, Lorgelly P,. 2008b. Should the capability approach be applied in health economics? Health Economics 17: 667-670.
18. Cuckle HS, Richardson GA, Sheldon TA, Quirke P,. 1995. Cost effectiveness of antenatal screening for cystic fibrosis. British Medical Journal 311; 1460-1464.
19. Davies L, Jones A, Vamvakas G, Dubourg R, Donmall M,. 2009. The Drug Treatment Outcomes Research study (DTORS): Cost-effectiveness analysis. The Home Office: London. ISBN 978 1 84987 124 2.
20. Dazord A,. 1995. Quality of life assessment in medicine: presentation of a new instrument (Subjective Quality of Life Profile (SQLP)) and first results. European Respiratory Review 5 (25): 66-71.
21. Department of Health. 2008. Guidance on the routine collection of Patient Reported Outcome Measures (PROMs). Available from: http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-092647. [Accessed May 2010].
22. Department of Health. 2010. Specialised Services National Definition Set: 20 Medical genetic services (all ages). 2010.http://www.dh.gov.uk/en/ Managingyourorganisation/Commissioning/Commissioningspecialisedservices/index. htm. [Accessed May].
23. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L,. 1974. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behavioural Science 19: 1-5.
24. de Bekker-Grob EW, Ryan ME, Gerard K,. 2012. Applying discrete choice experiments to value health and health care: a review of the literature. Health Economics 21 (2): 145-172.
25. Dolan P,. 2008. Developing methods that really do value the 'Q' in the QALY. Health Economics, Policy, and Law 3 (1): 69-77.
26. Donaldson C, Shackley P,. 1997. Does process utility exist? A case study of willingness to pay for laparoscopic cholecystectomy. Social Science & Medicine 44 (5): 699-707.
27. Donovan KA, Tucker DC,. 2000. Knowledge about genetic risk for breast cancer and perceptions of genetic testing in a sociodemographically diverse sample. Journal of Behavioral Medicine 23 (1): 15-36.
28. Doukas DJ, Li Y,. 2004. Men's values-based factors on prostate cancer risk genetic testing: a telephone survey. BMC Medical Genetics 5: 28-35.
29. Drummond MJ, Weatherly H, Ferguson B,. 2008. A broader perspective should include costs and benefits for all stakeholders. British Medical Journal 337: 770-771.
30. Ellison CW, Smith J,. 1991. Towards an integrative measure of health and well-being. Journal of Psychology and Theology 19 (1): 35-48.
31. Erblich J, Brown K, Kim Y, Valdimarsdottir HB, Livingston BE, Bovbjerg DH,. 2005. Development and validation of a Breast Cancer Genetic Counselling Knowledge Questionnaire. Patient Education and Counselling 56: 182-191.
32. Furr LA, Kelly SE,. 1999. The Genetic Knowledge Index: developing a standard measure of genetic knowledge. Genetic Testing 3: 193-199.
33. Glaser B, Strauss A,. 1967. The discovery of grounded theory. Aldine: Chicago.
34. Godfrey C, Stewart D, Gossop M,. 2004. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 99: 697-707.
35. Goldberg D, Williams P,. 1988. A users guide to the GHQ. NFER Nelson Publishing: Berkshire.
36. Grosse SD, Wordsworth S, Payne K,. 2008. Economic Methods for Valuing the Outcomes of Genetic Testing: Beyond Cost-Effectiveness Analysis. Genetics in Medicine 10 (9): 648-655.
37. Hall J, Viney R, Haas M,. 1998. Taking a count: the evaluation of genetic testing. Australian and New Zealand Journal of Public Health 22 (7): 754-758.
38. Herbert RJ, Gagnon AJ, Rennick JE, O'Loughlin JL,. 2009. A systematic review of questionnaires measuring health-related empowerment. Research and Theory for Nursing Practice 23 (2): 107-132.
39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X,. 2011. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research DOI 10.1007/s11136-011-9903-x.
40. Hibbard JH, Mahoney ER, Stockard J, et al,. 2005. Development and Testing of a Short Form of the Patient Activation Measure. Health Services Research 40: 1918-1930.
41. HM Treasury. 2001. The Green Book. Appraisal and evaluation in central government. TSO: London.
42. Holmes-Rovner M, Kroll J, Scmitt N, Rovner D, Breer L, Rothert ML, Padonu G, Talarczyk G,. 1996. Patient satisfaction with healthcare decisions: the satisfaction with decision scale. Medical Decision Making 15: 58-64.
43. Horsman J, Furlong W, Feeny D, Torrance G,. 2003. The Health Utilities Index (HUI®): concepts, measurement properties and applications. Health and Quality of Life Outcomes 1: 54-67.
44. Jarrett J, Mugford M,. 2006. Genetic health technology and economic evaluation. A critical review. Applied Health Economics and Health Policy 5 (1): 27-35.
45. Kash KM, Holland JC, Halper MS, Miller DG,. 1992. Psychological distress and surveillance behaviours of women with a family history of breast cancer. Journal of the National Cancer Institute 84: 24-30.
46. Kinghorn P, Robinson A, Smith R,. 2007. Developing the Capability Approach to Assess Quality of Life in Patients with Chronic Pain. International Health Economics Association Congress: Copenhagen.
47. Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, Reed MM,. 1997. Controlled trial of pre-test education approaches to enhanced informed decision making for BRCA1 gene testing. Journal of the National Cancer Institute 89 (2): 148-157.
48. Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A,. 1991. Psychological side effects of breast cancer screening. Health Psychology 10: 259-267.
49. Lipscomb J, Drummond M, Fryback D, Gold M, Revicki D,. 2009. Retaining, and enhancing, the QALY. Value in Health 12 (Suppl1): S18-S26.
50. Long AF, Hesketh A, Paszek G, Booth M, Bowen A, on behalf of the ACT NoW Study. 2008. Development of a reliable, self-report outcome measure for pragmatic trials of communication therapy following stroke: the Communication Outcome after Stroke (COAST) scale. Clinical Rehabilitation 22: 1083-1094.
51. Lorgelly PK, Lawson KD, Fenwick EAL, Briggs AH,. 2010. Outcome Measurement in Economic Evaluations of Public Health Interventions: a Role for the Capability Approach? International Journal of Environmental Research and Public Health 7: 2274-2289.
52. McAllister M, Davies LM, Payne K, Nicholls S, Donnai D, Macleod R,. 2007b. The emotional effects of genetic diseases: implications for clinical genetics. American Journal of Medical Genetics 143A: 2651-2661.
53. McAllister M, Dunn G, Todd C,. 2011a. Empowerment: Qualitative Underpinning of a New Patient Reported Outcome for Clinical Genetics Services. European Journal of Human Genetics 19: 125-130.
54. McAllister M, Payne K, MacLeod R, Nicholls S, Donnai D, Davies L,. 2008a. What process attributes of clinical genetics services could maximise patient benefits? European Journal of Human Genetics 16: 1467-1476.
55. McAllister M, Payne K, Macleod R, Nicholls S, Middleton-Price H, Donnai D, Davies LM,. 2008b. Patient empowerment in clinical genetics services. Journal of Health Psychology 13 (7): 895-905.
56. McAllister M, Payne K, Nicholls S, MacLeod R, Donnai D, Davies L,. 2007a. Improving service evaluation in clinical genetics: identifying effects of genetic diseases on individuals and families. Journal of Genetic Counseling 16: 71-83.
57. McAllister M, Wood A, Dunn G, Shiloh S, Todd C,. 2011b. The Genetic Counseling Outcome Scale: a new patient-reported outcome measure for clinical genetics services. Clinical Genetics 79: 413-424.
58. McNair DM, Lorr M, Droppleman LF,. 1981. Manual for the Profile of Mood States. Educational and Industrial testing Service (EdITS).
59. Miller SM,. 1987. Monitoring and blunting: validation of a questionnaire to assess styles of information seeking under threat. Journal of Personality and Social Psychology 52 (2): 345-353.
60. Mooney G,. 1994. What else do we want from our health services? Social Science & Medicine 39 (2): 151-154.
61. Mooney G, Lange M,. 1993. Ante-natal screening: what constitutes benefit. Social Science & Medicine 37 (7): 873-878.
62. Moos RH, Moos BS,. 1994. Family Environment Scale Manual. Consulting Psychologists Press.
63. MRC. 2008. Developing and evaluating complex interventions: new guidance. MRC: London.
64. NICE. 2008. Guide to the methods of technology appraisal. NICE: London.
65. NICE. 2009a. Methods for the development of NICE public health guidance. NICE: London.
66. NICE. 2009b. Guide to the methods of technology appraisal: addendum. NICE: London.
67. NICE. 2010. Diagnostics Assessment programme-interim methods statement pilot. NICE: London.
68. Payne K,. 2009. Fish and chips all round? Regulation of genetic-based technologies. Health Economics 18 (11): 1233-1236.
69. Payne K, Nicholls S, McAllister M, MacLeod R, Donnai D, Davies LM,. 2008. Outcome measurement in clinical genetics services: a systematic review of validated measures. Value in Health 11 (3): 497-508.
70. Payne K, Nicholls S, McAllister M, MacLeod R, Middleton-Price H, Ellis I, Donnai D, Davies LM,. 2007. Outcome measures for clinical genetics services: a comparison of genetics healthcare professionals and patients' views. Health Policy 84: 112-122.
71. Piggott M, Wilkinson P, Bennett J,. 1994. Implementation of an antenatal serum screening programme for Down's syndrome in two districts. Journal of Medical Screening 1: 45-49.
72. Read CY, Perry DJ, Duffy ME,. 2005. Design and psychometric evaluation of the psychological adaptation to genetic information scale. Journal of Nursing Scholarship 37 (3): 203-208.
73. Rogers ES, Chamberlain J, Ellison ML, et al,. 1997. A consumer-constructed scale to measure empowerment among users of mental health services. Psychiatric Services 48: 1042-1047.
74. Rogowski W,. 2006. Genetic screening by DNA technology. A systematic review of health economic evidence. International Journal of Technology Assessment in Health Care 22 (3): 327-337.
75. Rogowski W,. 2007. Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 80 (2): 340-357.
76. Rosenberg M,. 1965. Society & the Adolescent Self-Image. Princeton University Press.
77. Sadovnick AD, Baird PA,. 1981. A cost-benefit analysis of prenatal detection of Downs syndrome and neural tube defects in older mothers. American Journal of Medical Genetics 10: 367-378.
78. Sen A,. 1993. Capability and well-being. In the Quality of Life, Nussbaum MC, (ed.). Clarendon Press: Oxford.
79. Shiloh S, Avdor O, Goodman RM,. 1990. Satisfaction with genetic counselling: dimensions and measurement. American Journal of Medical Genetics 37: 522-529.
80. Smith RD,. 2003. Construction of the contingent valuation market in health care: a critical assessment. Health Economics 12 (8): 609-628.
81. Stalmeier PF, Roosmalen MS, Verhoef LC, Hoekstra-Weebers JE, Oosterwijk JC, Moog U, Hoogerbrugge N, van Daal WA,. 2005. The decision evaluation scales. Patient Education and Counseling 57 (3): 286-293.
82. Strauss A, Corbin J,. 1990. Basics of qualitative research: Grounded theory procedures and techniques. Sage Publications: London.
83. Tercyak KP, Johnson SB, Roberts SF, Cruz AC,. 2001. Psychological response to prenatal genetic counselling and amniocentesis. Patient Education and Counselling 43: 73-84.
84. Torrance N, Mollison J, Wordsworth S, Gray J, Miedzybrodzka Z, Haites N, Grant A, Campbell M, Watson MS, Clarke A, Wilson B,. 2006. Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials. British Journal of Cancer 95: 435-444.
85. Trask P, Paterson AG, Wang C, Hayasaka H, Milliron K, Blumberg L, et al,. 2001. Cancer-specific worry interference in women attending a breast and ovarian cancer risk evaluation program: impact on emotional distress and health functioning. Psycho-Oncology 10: 349-360.
86. Ware JE,. 1993. SF-36 Health survey: manual and interpretation guide. Health Institute, New England Medical Centre.
87. Westbrook MT,. 1979. A classification of coping behaviour based on multidimensional scaling of similarity ratings. Journal of Clinical Psychology 35 (2): 407-409.
88. Zigmond AS, Snaith AP,. 1983. The hospital anxiety and depression scale. Acta Psychiatrica Scandanavica 67: 361-370.
89. Zung WK,. 1986. Zung self-rating depression scale and depression status inventory. In Assessment of Depression, Sartorius N, Ban T, (eds). Springer: Berlin.